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Abstract The presence of disseminated tumor cells
(DTCs) in the bone marrow (BM) of breast cancer patients
is prognostic for early relapse. In the present study, we
analyzed the gene expression profiles from BM cells of
breast cancer patients to identify molecular signatures
associated with DTCs and their relevance to metastatic
outcome. We analyzed BM from 30 patients with stage II/
III breast cancer by gene expression profiling and corre-
lated expression with metastatic disease development. A
candidate gene, PITX2, was analyzed for expression and
phenotype in breast cancer cell lines. PITX2 was knocked
down in the MDAMB231 cell lines for gene expression
analysis and cell invasiveness. Expression of various sig-
naling pathway molecules was confirmed by RT–PCR. We
found that the expression of Paired-like Homeobox Tran-
scription factor-2 (PITX2) is absent in the BM of normal
healthy volunteers and, when detected in the BM of breast
cancer patients, is significantly correlated with early
metastatic disease development (p = 0.0062). Suppression
of PITX2 expression significantly reduced invasiveness in
MDAMB231 cells. Three genes—NKD1, LEF1, and
DKK4—were significantly downregulated in response to
PITX2 suppression. Expression of PITX2 in BM of early-
stage breast cancer patients is associated with risk for early
disease recurrence. Furthermore, PITX2 likely plays a role
in the metastatic process through its effect on the expres-
sion of genes associated with the Wnt/beta-Catenin sig-
naling pathway.
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Introduction
Metastatic spread of breast cancer is the major cause of
mortality in patients. Although thousands of cells are shed
from primary tumors, only a few cells possess the potential
to give rise to metastatic foci [1, 2]. The metastatic process
consists of a series of steps, all of which must be success-
fully completed to form a metastatic focus [3–6]. These
include shedding of cells from a primary tumor into the
circulation, survival of the cells in the circulation, arrest in
the vasculature of a new organ, extravasation into the sur-
rounding tissue, initiation and maintenance of growth, and
vascularization of the metastatic tumor [7]. To halt the
metastatic process, it is essential to identify those interme-
diary cells with metastatic potential which are often
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resistant to chemotherapy, understand their biology through
molecular characterization, and target their therapeutic
vulnerabilities. The small number of disseminated, pre-
metastatic tumor cells found in the circulation has previ-
ously hindered studies on the metastatic process. In breast
cancer patients, clinical studies suggest that bone marrow
(BM) serves as a reservoir for the disseminated tumor cells
(DTCs), which are thought to be precursors to metastatic
foci [8]. DTCs can survive in the BM for long periods of
time, and their presence in BM portends an increased risk of
distant disease development [9, 10]. Detection of DTCs in
BM after chemotherapy treatment is an indicator of par-
ticularly poor prognosis suggesting that those cells which
survive cytotoxic chemotherapy have greater metastatic
potential [11]. Focusing on the DTC population that is
present after chemotherapy treatment could lead to a better
understanding of the molecular mechanisms that contribute
to metastatic potential of the DTCs.
Earlier studies from our lab identified 67 genes that were
overrepresented in DTCs enriched from the BM of stage II/
III breast cancer patients after chemotherapy treatment
[12]. Among these, expression of five genes, TWIST1,
PITX2, S100A3, PDGFRL, and DUSP9, was not detected
in BM from healthy volunteers suggesting that expression
most likely emanates from DTCs residing in the BM of the
breast cancer patients.
Paired-like homeobox transcription factor-2 (PITX2) is a
bicoid-related homeobox transcription factor that is
involved in pituitary-specific gene regulation and left–right
patterning during embryonic development [13–15]. PITX2,
as observed with other metastatic disease regulators such as
TWIST1, may also be involved in epithelial-mesenchymal
transition (12). PITX2 has three alternative transcripts
resulting in 3 isoforms 1, 2, and 3 [16, 17]. Promoter P1
drives the transcription of the isoform 3 [18]. Isoforms 1 and
2 are driven by a common promoter, P2 [19]. Expression of
isoforms 1 and 2 is regulated by WNT pathway and
expression of isoform 3 is regulated by TGF-b family
members [18–20]. Methylation of P2 in primary tumors has
been reported to be an indicator of high risk for disease
recurrence in hormone receptor-positive, node-negative
breast cancer patients [19]. In this study, we investigated the
role of PITX2 in regulating invasive potential and specific
gene expression programs in breast cancer cells which may
mediate the pro-invasive action of PITX2.
Materials and methods
Patient population and BM collection
BM collected from 30 patients with clinical stage II/III
breast cancer who had been enrolled into a prospective
clinical trial March 2003 and March 2006 as previously
described between (12). Median follow-up is approxi-
mately 10 years. The protocol was approved by the insti-
tutional review board of Washington University and all
patients signed written informed consent. BM was col-
lected from each iliac crest at the time of diagnosis, after 4
cycles of epirubicin/taxotere, and 1 year after diagnosis
(12). BM samples from each iliac crest collected prior to
any treatment were used to determine the relationship of
gene expression to recurrent disease development. Half of
the 30 patients developed recurrent disease within
16 months of diagnosis. Control BM specimens were col-
lected from healthy female volunteers after informed
consent.
RNA isolation and qRT–PCR
Whole BM samples were subjected to hypotonic RBC
lysis, 5 9 106 nucleated cells were pelleted and snap fro-
zen for subsequent RNA isolation. Total RNA was isolated
using Trizol reagent (Invitrogen) according to manufac-
turer’s recommendations. RNA from cell lines was isolated
using the same protocol. 1 lg of RNA was used for syn-
thesis of first strand cDNA using the Retroscript (Ambion)
kit with random hexamers. Resulting cDNA was diluted to
an equivalent of 10 ng/lL of input RNA.
qRT–PCR for the indicated genes was performed as
described previously [12]. Primer/probe sets were pur-
chased from Applied Biosystems. Each reaction consisted
of 2 lL of cDNA, TaqMan Master Mix (Applied Biosys-
tems), and primer/probe set in a total volume of 20 lL. The
expression of the three PITX2 transcript variants was
determined by qRT–PCR using SybrGreen Universal
master mix (ABI, California). Primer sets for isoform 1 and
isoform 2 were designed as described in Nimmrich et al.
[19] (isoform 1 forward GCGTGTGTGCAATTAGA-
GAAAG and reverse CCGAAGCCATTC TTGCATAG;
isoform 2 forward GCCGTTGAATGTCTCTTCTC and
reverse CCTTTGCCGCTTCTTCTTAG). Isoform 3 was
detected using the primers—forward GCT TCACTTG-
GAGCACCGAGCA, and reverse GAGGTGTCGGA-
GATGGTGTG. For each transcript/sample, triplicate
reactions were analyzed in an ABI 7500 FAST Sequence
Detection System. The Ct values of each gene were nor-
malized to GAPDH Ct values for the same sample (dCt)
and compared with that of BM of four normal healthy
volunteers to calculate the ddCt and fold overexpression.
Cell culture and stable transductions
Breast cancer cell lines MDAMB231, MCF7, MCF10A,
T47D, ZR75, and SKBR3 were purchased from ATCC.
MDAMB231 cells were grown in DMEM containing 10 %
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fetal bovine serum (FBS). MCF7 and MCF 10A cells were
grown in a mixture of 50 % MEGM (Lonza) and DMEM
with 10 % FBS, ZR75 was grown in RPMI containing
10 % FBS. SKBR3 and T47D were grown in McCoy’s
media with 10 % FBS. All cells were grown at 37 C with
5 % CO2.
RNA expression level of each of the 3 PITX2 isoforms
was quantified by qRT–PCR using specific primers
designed for each isoform in human breast cancer cell lines
listed above. PITX2 expression was stably silenced in
MDAMB231 cell line, which had high endogenous levels
of all three PITX2 transcript isoforms, using Mission len-
tiviral transduction particles (Sigma, St. Louis) and
selecting the stably transduced cells with puromycin. The
construct targeted all three isoforms (TRCN000002479).
Individual clones were selected and tested for PITX2
expression and several PITX2 knockdown clonal lines were
established.
Matrigel invasion assay
MDAMB231 cells with near total knockdown of the PITX2
gene were used for matrigel invasion assays (BD Bio-
sciences) and performed according to the manufacturer’s
recommendations. Briefly, cells were suspended in growth
factor-free media. 3 9 104 cells were added to each well of
an invasion chamber which contained growth factor-free
media. Complete growth medium was added to the lower
chamber as chemoattractant. The number of invasive cells
was counted at 24 h and 48 h after seeding. MDAMB231
cells transfected with empty vector, a non-targeting
sequence, or shRNA against the unrelated gene, beta-2
microglobulin, served as negative controls. The number of
invasive cells was counted from five random fields from
each well and total cells counted for each well were cal-
culated for subsequent statistical analysis. All experiments
were repeated three times.
Wnt pathway expression analysis
MDAMB231 cells with PITX2 gene knockdown and con-
trols were used for gene expression analysis. Three dif-
ferent clonal lines of stably knocked down PITX2 gene
were grown in two wells of a six-well plate. A similar set
of cells that were stably transduced with a non-targeting
sequence were grown in parallel. Two wells of the same
clonal line of PITX2 knockdown or non-targeting sequence
were pooled and used for RNA extraction as described
earlier. Samples were analyzed for gene expression using
Taqman 96 well Array plates (Applied Biosystems)
according to manufacturer’s protocol. The relative
expression of each gene with respect to GAPDH levels of
corresponding samples was determined and the average of
four samples in each group was used for subsequent ddCt
and fold difference calculation.
Analysis of data
For PCR analysis, fivefold increased expression over nor-
mal BM was considered positive. Patient BM was con-
sidered positive if BM from at least one side (right or left)
over-expressed the gene. Gene expression from patient
samples and survival were analyzed using Kaplan–Meier
model and Cox proportional hazards models. All estimates
are derived from single-variable models, i.e., fold change
in only 1 gene was included in each model. For the inva-
sion experiments, percentage invasion was calculated as
the percentage of number of cells passed through the
Matrigel to the total number of cells present before harvest.
Significant difference between samples was analyzed using
paired t test.
Results
TWIST1 and PITX2 are expressed in BM of patients
who develop recurrent disease
We had earlier identified a 67-gene signature associated
with the presence of DTCs in the BM of breast cancer
patients using gene array analysis (Supplemental Table 1)
[12]. Within the 67-gene signature, 5 genes, TWIST1,
PITX2, S100A3, PDGFRL, and DUSP9, were highly
expressed in breast cancer cell lines and had no
detectable expression in normal human BM by qRT–PCR
(Supplemental Table 2). Expression of these 5 genes as well
as Keratin 19 (KRT19) and 5 other genes from the 67-gene
signature (HSP27, IGF, PIR, SlAC2, SNAIL1) were exam-
ined in 50 BM specimens collected from 30 patients with
clinical stage II/III breast cancer prior to any treatment. 20
patients had BM collected from both the right and left iliac
crests which were analyzed individually and 10 patients had
the right and left BM pooled prior to analysis (Table 1).
Thirteen (43 %) of these patients developed recurrent dis-
ease within 16 months of diagnosis. All sites of visceral
metastases were visceral except for one patient who devel-
oped contralateral axillary metastases. Approximately half
of the patients (47 %), in the metastatic group and non-
metastatic group, had triple negative cancers (Table 2).
Using a threshold of fivefold higher than pooled BM con-
trols, TWIST1 was elevated in 3 BM specimens from 2
patients, both of whom developed distant recurrent breast
cancer and PITX2 was elevated in 7 BM specimens from 5
patients, 4 of whom developed distant recurrent breast
cancer within 16 months of diagnosis. TWIST1 and PITX2
expression in patient BM were found to correlate
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Table 1 Relative expression
levels of TWIST1, PITX2, and
KRT19 in BM specimens from
clinical stage II/III breast cancer
patient bone marrows collected
prior to therapy
Patient # Site Histology ER PR Her-2 Recurrence site *Twist-1 *PITX2 *KRT19
1 R IDC neg neg pos NT 1.55 0.42
L IDC neg neg pos 0.85 1.24 1.35
2 L IDC neg neg neg Lung 0.62 0.30 0.71
R IDC neg neg neg Lung 0.95 0.51 0.33
3 R IDC pos neg pos 0.92 0.53 7.47
L IDC pos neg pos 0.52 0.73 5.59
4 L IDC neg pos neg Lung 3.08 0.94 2.65
R IDC neg pos neg Lung 0.23 3.35 0.34
5 L IDC neg neg neg Liver 9.05 42.19 0.57
R IDC neg neg neg Liver 27.86 91.71 1.75
6 X IDC neg neg neg 0.93 1.52 0.23
X IDC neg neg neg 0.47 1.65 3.66
7 R IDC neg neg neg Liver ND 1.25 0.53
L IDC neg neg neg Liver 0.41 0.89 3.98
8 R IDC pos pos neg ND 3.47 0.76
9 R IDC pos neg neg Liver, bone 1.16 13.99 7.85
L IDC pos neg neg Liver, bone 1.91 23.75 0.23
10 R IDC neg neg neg 0.67 0.71 3.05
L IDC neg neg neg 1.33 5.82 0.56
11 R IDC neg neg neg ND ND 0.40
L IDC neg neg neg 0.34 0.98 1.11
12 L IDC neg neg pos 0.47 1.93 0.93
R IDC neg neg pos 0.51 0.51 0.19
13 L IDC pos pos neg ND ND ND
R IDC pos pos neg 0.79 2.23 0.60
14 L IDC neg neg pos Brain 0.68 2.28 0.68
R IDC neg neg pos Brain 0.61 16.71 0.47
15 L IDC neg neg neg 0.83 1.42 5.82
R IDC neg neg neg 0.56 1.40 0.12
16 L ILC neg neg neg Liver, pancreas 0.42 6.24 3.28
17 X IDC pos pos neg 0.96 0.41 1.09
18 R IDC pos neg neg Liver, lung, bone 0.37 0.24 0.17
L IDC pos neg neg Liver, lung, bone 1.49 0.30 3.25
19 X IMC neg neg neg 0.32 0.42 0.87
20 L ILC neg neg neg Liver, bone 0.78 0.68 0.10
R ILC neg neg neg Liver, bone 1.20 0.91 0.44
21 R IDC neg neg pos Contralateral axilla ND 0.75 0.55
L IDC neg neg pos Contralateral axilla 0.32 0.36 0.54
22 L IDC neg neg neg 0.91 0.69 0.17
R IDC neg neg neg 0.62 1.77 0.35
23 L IMC pos pos neg Brain, liver 1.16 1.70 0.64
R IMC pos pos neg Brain, liver ND 2.08 0.12
24 X ILC pos neg neg 1.10 1.16 0.96
25 R ILC neg pos pos Liver 1.30 0.92 1.12
26 R IDC neg pos neg ND 2.55 0.52
27 X IDC pos pos neg 0.21 3.13 0.33
28 L IMC pos pos neg 0.19 0.53 3.39
R IMC pos pos neg 0.47 3.60 2.01
29 R IDC neg neg pos Liver, lung 1.63 0.56 6.27
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significantly with the development of early recurrent disease
(p = 0.005 and 0.0062, respectively) (Table 3).
PITX2 is expressed in breast cancer cell lines
with invasive phenotype
Since PITX2 was not expressed in the normal BM and its
expression in BM from stage II/III breast cancer patients
significantly correlated with early recurrent disease devel-
opment, we sought to determine the expression levels and
physiological function in established breast cancer cell
lines. PITX2 has 3 isoforms (Fig. 1). The expression of each
isoform in six breast cancer cell lines with varying meta-
static potential was determined by qRT–PCR. The highly
metastatic breast cancer cell line MDAMB231 expressed all
three isoforms of PITX2 at different relative levels. Isoform
1 was fourfold higher in MDAMB 231 than in the next
highest PITX2 expressing cell line, CA1A. In this cell line,
which is also can form metastases [21] [12], only isoform 1
was detected. The expression of all isoforms of PITX2 in
MCF10A and ZR75, both of which are non-invasive, was
very low to undetectable. MCF-7 and T47D, both of which
are non-metastatic, expressed isoform 3. The two invasive
cells lines tested expressed high levels of isoform 1, which
has been reported to be important in the Wnt/beta-catenin
pathway while the non-invasive cell lines expressed either
no/low levels of PITX2 or isoform 3, which is in the TGF-
beta pathway. The relative level of expression of the 3
isoforms of PITX2 in cell lines is shown in Fig. 2.
Knockdown of PITX2 reduces invasiveness
in MDAMB231 cells
To determine whether PITX2 plays a role in cell invasive-
ness, we performed gene knockdown experiments using the
MDAMB231 cell line. MDAMB231 is highly invasive and
has relatively high expression of all three of PITX2 iso-
forms. Using a lentivirus shRNA system, PITX2 expression
was reduced to near undetectable level as determined by
qRT–PCR. Clonal cell lines with the highest level of
knockdown were selected for invasion assays. MDAMB231
cells stably transduced with empty vector, a non-targeting
sequence, or shRNA targeting an unrelated gene, beta-2
microglobulin, were included as controls. The relative
expression of PITX2 in each cell type used is shown in
Fig. 3c. The knockdown cells (KO) had undetectable ex-
pression of PITX2, while the control cell lines expressed
similar levels of PITX2. The percentage of cells which
migrated into the lower chamber of the invasion cassette is
shown in Fig. 3b. Cells with reduced PITX2 expression
showed a significant reduction in invasion compared to all
control cells, both at 24 and 48 h after plating (Fig. 3a, b).
There was a 63.8 % reduction in invasion in PITX2 defi-
cient cells at 24 h and 72.6 % reduction at 48 h compared to
the parental cells (p\ 0.0001). These data suggest that loss
of PITX2 expression attenuates the invasive phenotype of
MDAMB231 cells.
PITX2 mediates the expression of genes associated
with aggressive tumors
PITX2 isoform 1 is a component of the Wnt/beta-Catenin
pathway and is a downstream target of LEF1 [13]. The
Wnt/beta-Catenin pathway is known to contribute to tumor
invasion and metastasis [22, 23]. We hypothesized that loss
of the invasive phenotype associated with downregulation
of PITX2 in MDAMB231 cells was mediated through the
Wnt pathway. To test the effect of PITX2 knockdown on
the Wnt pathway signaling program, we analyzed the gene
expression pattern of genes in the Wnt pathway as well as
other pathways, by qRT–PCR using modified Wnt pathway
arrays. Four sets of independent PITX2 knockdown cells
and four sets of mock transfected cells were used for
analysis. The expression of 96 genes was analyzed which
represented the Wnt/beta-catenin pathway, EMT, and
TGF-beta pathways (Supplemental Table 3). The statistical
significance in the expression of each gene in the two
experimental groups was determined. Of the 96 genes
examined, only the expression of three genes, NKD1,
Table 2 Tumor biomarkers of the patient specimens analyzed
No mets Mets
Number (%) Number (%)
Total number 17 13
ER? 6 (35) 3 (23)
Her2? 2 (12) 4 (30)
ER?/Her? 1 (5) 0 (0)
TN 8 (47) 6 (46)
Table 1 continued
Patient # Site Histology ER PR Her-2 Recurrence site *Twist-1 *PITX2 *KRT19
30 X IDC neg neg neg 0.34 0.90 3.29
Site- site of BM collection, right or left iliac crest, Histology- IDC, invasive ductal carcinoma; ILC,
invasive lobular carcinoma; IMC, invasive mammary carcinoma. PCR values are expressed as fold change
in gene expression relative to normal human BM
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Table 3 Estimate of the effect of fold change in gene expression on time to recurrence in the 30 patients
Gene tested p value Hazard ratio Lower limit of 95 % confidence
interval for hazard ratio
Upper limit of 95 % confidence
interval for hazard ratio
PITX2 0.0062 1.09 1.02 1.16
TWIST1 0.005 1.71 1.18 2.48
HSPB27 0.0139 6.66 1.47 30.18
DUSP9 0.6 0.76 0.27 2.13
ID1 0.99 0.99 0.85 1.17
IGF 0.61 1.11 0.73 1.69
KRT19 0.79 1.04 0.78 1.38
PDGFRL 0.27 1.13 0.91 1.4
PIR 0.23 0.71 0.4 1.24
S100A3 0.74 0.9 0.5 1.63
SLAC2 0.44 0.85 0.58 1.27
SNAIL1 0.2 0.44 0.13 1.53
All estimates are derived from single-variable models; in other words, fold change in only 1 gene has been included in each model. PITX2,
TWIST1, and HSPB27 are statistically significantly related to time to recurrence
1 - 572 573 -
628
629 - 834 835 - 2100Isoform 1
1 - 572 573 -
628
629 - 766 767 - 972 973 - 2238Isoform 2
1050 - 23151 - 843 844 -1049Isoform 3
1 2 3 64 5Exons
P2 P1
Fig. 1 Diagram showing the alternate splice variants of PITX2. The general exon arrangement and promotor location is shown in the top and
exon structure of each isoforms are shown subsequently
Fig. 2 Relative expression
pattern of PITX2 isoforms in
breast cancer cell lines by qRT–
PCR. Expression of each
isoform relative to four normal
human BM samples
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LEF1, and DKK4, was significantly reduced as a result of
PITX2 knockdown (Table 4). All three of these genes have
been reported to contribute to an aggressive tumor phe-
notype and metastases development and are in the
Wnt/beta-Catenin pathway. Our results suggest that PITX2
plays a role in mediating invasiveness in cancer cells
through the Wnt/beta-Catenin pathway and not the TGF-B
or through EMT.
Discussion
Identification of the molecular mechanisms behind the
metastatic process is essential for elimination of minimal
residual disease and preventing cancer recurrence. The
presence of DTCs in the BM of breast cancer patients
before and after chemotherapy has been reported as an
independent predictor of prognosis [9, 11]. However, the
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Fig. 3 Matrigel invasion assays showing reduced invasion in
MDAMB231 cells with PITX2 knockdown. a Top panel shows the
cells in the matrigel invasion chamber prior to the clearing of the top
chamber. Cells present both at the top chamber and invaded cells in
the bottom chamber are visible. Bottom panel shows cells after
clearing the top chamber; thus, only those cells invaded to bottom
chamber are visible. Different derivatives of cells used in the
experiment are indicated. Statistical significance by paired t test in
comparison with non-transduced MDAMB231 cells are shown.
(MDAMB231- non-transduced parental cells, pLKO vector—trans-
duced with empty vector, Non-targeting—transduced with a non-
targeting sequence, B2M—transduced with shRNA of an unrelated
gene beta-2 microglobulin, ko- PITX2—transduced with shRNA of
PITX2.) b Percentage of cells present in bottom chamber at 24 and
48 h. c Expression levels of PITX2 in the cells used for experiment as
determined by qRT–PCR
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rarity and biochemical heterogeneity of DTCs have hin-
dered studies focused on defining their molecular features
and therapeutic vulnerabilities. Previously, we analyzed the
BM of breast cancer patients and identified a molecular
signature associated with early disease relapse. In this
manuscript, we demonstrate that one of the genes in this
signature, PITX2, identifies patients with who are at risk for
developing early recurrent disease and which likely plays a
role in the invasiveness of a breast cancer cells through the
Wnt/beta-Catenin pathway.
We employed gene expression analysis of BMs col-
lected from breast cancer patients to determine the specific
molecular features of DTCs. Those genes which were
expressed in the BM of patients but had no expression in
the BM from healthy volunteers were considered to be
derived from cancer cells lodged in the BM. Since DTCs
are known to be heterogeneous, it is likely that only a
subpopulation of the detectable DTCs have the potential to
progress to a metastatic focus. Therefore, we correlated the
expression of DTC-associated genes to metastatic outcome
and time to recurrence. Of the genes examined, expressions
of TWIST1 and PITX2 in the BM of breast cancer patients
were found to be significantly associated with metastatic
disease development in this analysis. The number of
patients with detectable TWIST1 or PITX2 in their BM was
14 % (7 of 30 patients) which identified 46 % (6 of 13
patients) of the patients who subsequently developed
metastatic disease.
The role of TWIST1 is well documented in the EMT
process and metastasis of cancers [24] and we have pre-
viously reported on its significance in the BM of breast
cancer patients [12]. The role of PITX2 in tumorigenesis in
general and its association with metastatic process in par-
ticular are not as well understood. PITX2 is a pituitary
homeobox transcription factor responsible for embryonic
development of organs and morphogenesis. One of the
transcript variants, isoform 3 is responsible left right
symmetry during development. There are several recent
reports on the association of PITX2 expression in various
neoplasms. Upregulation of PITX2 has been reported in
pituitary adenomas, colorectal cancers, and Wilms tumors
[25–27]. A recent study demonstrated that PITX2 expres-
sion activates tumor progression and invasion in ovarian
cancer, possibly independent of Wnt/beta-Catenin pathway
[28]. In contrast, promoter methylation and subsequent
silencing has been associated with certain prostate [29] and
breast [19, 30] cancers specifically estrogen receptor-pos-
itive cancers. These data suggest that the mechanism of
PITX2 in tumor progression may vary depending on the
tumor type.
Our results indicate that PITX2 could play a direct
role in the metastatic phenotype of breast cancer. Pre-
sumptive expression by DTCs is significantly correlated
with early disease recurrence and experimental evidence
that gene suppression reduces the invasive phenotype in
MDAMB231 cells reinforces this notion. Interestingly,
we were unable to develop stable long-term knockdowns
of PITX2 in MDAMB231 cells and thus were unable to
perform animal experiments. This may indicate an
essential role of PITX2 in the stability of the cancer
cells.
In our system, PITX2 appears to mediate its effects
through the Wnt/beta-Catenin pathway rather than other
pathways associated with PITX2 such as the TGF-beta
pathway. Three genes, NKD1, LEF1, and DKK4 signifi-
cantly downregulated by PITX2 knockdown, are known
to contribute to tumorigenesis and metastasis through
activation of Wnt pathway (Fig. 4). Activation of the
Wnt/beta-Catenin results in high levels of NKD1 [31]. It
has been reported that loss of function mutation in
NKD1 can alter Wnt signaling and contribute to
enhanced tumorigenesis [32]. However, the full pathway
between Wnt/beta-Catenin and NKD1 activation has not
yet been elucidated. High levels of DKK4 have been
reported to increase migration and invasion properties in
colon cancer cells and its downregulation may have anti-
cancer action [33]. DKK4 is downstream target of
TCF/beta Catenin, and its high expression indicates
activated state of Wnt signaling pathway [34]. It is
known that PITX2 transactivates the LEF1 promoter and
also enhances the endogenous expression of the full
length beta-Catenin-dependent isoform. LEF1 is a
downstream component of Wnt signaling and is known
to contribute to invasion in breast cancer cells [35]. The
Wnt signaling pathway mediated through the TCF/LEF1
transcriptional activator complex is activated in lung
adenocarcinoma metastases [22]. Thus, PITX2 likely
contributes to cell division, proliferation, and migration
through mediating differential LEF1 isoform expression
and subsequent interactions with LEF1 and beta-Catenin
[36].
Table 4 Relative expression of genes associated with Wnt pathway
Gene Fold difference between





The expression levels of various genes involved in Wnt pathway in
PITX2 depleted and control MBAMB231 cells were determined by
qRT-PCR. Four independent sets of PITX2 depleted clones and mock
transduced cells were used in the analysis. The values were normal-
ized to GAPDH and the fold difference calculated by ddCt method.
The statistical significance in PITX2 expression was calculated by
t Test
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As illustrated in Fig. 4, all three genes, NKD1, LEF1,
and DKK4, found to be downregulated with PITX2
knockdown are consistent with activation of the Wnt
signaling pathway by PITX2. Although DKK4 and NKD1
are Wnt pathway antagonists [37, 38], their elevated
levels are indicative of activated Wnt/Beta-catenin sig-
naling as both of them are transcriptionally activated by
the TCF/LEF complex. Since LEF1 is a downstream
target of PITX2 transactivation, reduced levels of NKD1
and DKK4 are expected as consequence of PITX2
downregulation. Even though the expression of two Wnt
pathway antagonists are diminished as a result of PITX2
knockdown, the Wnt pathway remains abrogated pri-
marily due to the reduced transcription of LEF1 which is
the major transcriptional co-activator effecting the path-
way [39].
Our results suggest that PITX2 expression in the BM of
breast cancer patients is indicative of the presence of DTCs
and is a predictor of high risk for metastatic disease
development. PITX2 contributes to the invasiveness of
breast cancer cells, and this appears to be mediated through
the Wnt/beta-Catenin pathway. It is possible that thera-
peutically targeting PITX2 or its downstream activators




























Fig. 4 Canonical Wnt pathway illustrating the roles of PITX2
dependant genes. Solid lines indicate activated state and discontin-
uous lines indicated inhibited state of the pathway. Genes highlighted
in yellow shapes showed significant reduction upon PITX2 downreg-
ulation. When activated by the Wnt ligands, the Frizzled/LRP1/6
receptor complex inhibits the GSK3/Axin/APC complex and
stabilizes beta-Catenin. Subsequently beta-Catenin facilitates the
nuclear translocation of TCF/LEF complex resulting in the transac-
tivation of target genes including PITX2, NKD1, DKK4, and several
other genes contributing to invasion and metastasis. NKD1 antago-
nizes the Wnt pathway as transcriptional repressor and also by
mediating the degradation of DVL1
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towards eliminating minimal residual disease and
micrometastases in high risk women.
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